By Economic Times – Covishield and Covaxin: All you need to know about India’s coronavirus vaccines 04 Jan 2021, 02:24 PM ISTOxford-AstraZeneca made Covishield by genetically engineering adenovirus that normally infects chimpanzees. It uses double-stranded DNA. Bharat Biotech made Covaxin is based on an inactivated form of the coronavirus.Reuters2/5How effective are they?As per clinical trial results, Covishield demonstrated 70%-90% efficacy. On the other hand, Covaxin’s efficacy rate is still not known. However, studies on monkeys and hamsters found that it provided protection against infection. Phase 1/2 trial showed that the vaccine didn’t cause any serious side effects while producing antibodies to the coronavirus. Covaxin has been evaluated in approximately 1,000 subjects in Phase I and Phase II clinical trials. Bharat Biotech said it will soon submit data on Covaxin soon.PTISerum Institute of India (SII), which manufactures the Covishield vaccine, claimed that it can give 10 million doses in January to the Government of India and can further ramp of production on demand. On the other hand, Bharat Biotech has still not started mass production of its Covaxin.ReutersSII had earlier said that it can supply vaccines to the govt at Rs 200 per dose and at Rs 1,000 per dose for private use. Bharat Biotech is yet to announce the price of Covaxin.There are two full dosages of SII’s Covishield. However, there is confusion on the interval. Oxford-AstraZeneca’s dosage information has created confusion about whether the two doses should be given at 2 months interval or three. There is also confusion whether people should give two full doses or 1 and 1/2 dose.
For more details, please visit http://gestyy.com/ethAGK